{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 45,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/4",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.04,
        "y": 0.007
      },
      "kind": "callout",
      "text": "Management & Programs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ded14a1-6b67-4325-96f2-c01ab165b64e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.04,
        "y": 0.0044
      },
      "kind": "callout",
      "text": "Overview",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9233028b-ed70-4fa2-a965-c914bf63a4d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.04,
        "y": 0.0018
      },
      "kind": "callout",
      "text": "Transaction Summary",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e379fc33-4224-4322-9a1b-5898ba351d76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.26,
        "y": 0.0075
      },
      "kind": "list",
      "text": "Existing Enliven management to lead the combined company. New Board of Directors will include 9 members (8 existing Enliven, 1 existing Imara). Combined company will focus on advancing the development of Enliven programs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68805790-5fb0-47a0-9d65-21aee1709917",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.7,
        "x": 0.26,
        "y": 0.0043
      },
      "kind": "list",
      "text": "Expected ownership is approximately 84% Enliven (including those purchasing Enliven shares in the private financing), 16% Imara, subject to adjustment based on Imara’s net cash at closing. Projected $82.3 million net cash and cash equivalents from Imara and an additional $164.5 million of cash from concurrent financing. CVR agreement to provide additional consideration to Imara stockholders if milestone payments are received from the previously announced pending sale of tovinontrine (IMR-687) or a potential sale or license involving IMR-261. Merger and concurrent financing expected to close in 1Q 2023.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a7c93b6-6ed6-4068-b7c7-8065cf009551",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.26,
        "y": 0.0019
      },
      "kind": "list",
      "text": "Merger with Enliven, a privately held precision oncology company. Strong balance sheet of approximately $300 million of cash and cash equivalents expected to provide funding for operations into early 2026. Upon close, company expected to be renamed “Enliven Therapeutics, Inc.” trading as Nasdaq: ELVN. Supported by the Board of Directors of both companies and is subject to shareholder approval and other customary closing conditions.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "927e2d33-8d67-4556-810f-e58c8dd3ba7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "Merger of Enliven and Imara",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "292c6eb9-91ab-4be8-95ff-da24e4e16a4a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a2a27cc7-e663-48ea-b40c-b53e7024a7e2",
      "evidence": "The document presents the merger as a way to create a clinical-stage, precision oncology company with multiple opportunities for growth and innovation.",
      "position": 1,
      "objective": "Why is precision oncology important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}